[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cushing-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cushing-syndrome":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,18,0,[8,45,71,98,130,181,210,235,258,282,310,338,363,386,410,434,459,480],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100501085","phase-1-a-study-to-evaluate-the-safety-and-pk-of-crn04894-for-the-treatment-of-cushings-syndrome-100501085",false,"NCT05804669","A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome","A Phase 1b\u002F2a Open-label Multiple-ascending Dose Exploratory Study of CRN04894 in ACTH-dependent Cushing's Syndrome (Cushing's Disease or Ectopic ACTH Syndrome)","Inclusion Criteria:\n\n1. Adult male or female, aged 18 years or more\n2. Evidence of chronic 'active' ACTH-dependent Cushing's syndrome\n3. Evidence of acutely 'active' ACTH-dependent Cushing's syndrome within 10 days of Day 1\n4. Participants with documented ACTH-dependent Cushing's syndrome taking short-acting steroidogenesis inhibitors (ketoconazole, levoketoconazole, osilodrostat, or metyrapone) may participate after a washout period of at least 5 days, if they meet other study inclusion criteria, relative to Investigator's judgment. Participants with documented ACTH-dependent Cushing's syndrome taking cabergoline may participate after a washout period of at least 14 days, if they meet other study inclusion criteria\n\nExclusion Criteria:\n\n1. Women who are pregnant or lactating\n2. History of bilateral adrenalectomy\n3. Previous pituitary MRI findings of a putative ACTH-secreting lesion within 3 mm of the optic chiasm\n4. Presence of any known malignancy\n5. Use of mitotane\n6. Previous unsuccessful surgery for Cushing's syndrome within 6 weeks","ALL","18 Years",{"count":5,"type":19},"ESTIMATED","INTERVENTIONAL",[22,23],"PHASE1","PHASE2","A Phase 1b\u002F2a, first-in-disease, open-label, multiple-ascending dose exploratory study to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamic biomarker responses associated with CRN04894 (an adrenocorticotropic hormone \\[ACTH\\] receptor antagonist) in participants with ACTH-dependent Cushing's syndrome (Cushing's disease or Ectopic ACTH Syndrome \\[EAS\\])",[26,27,28],"Cushing Syndrome","Cushing Disease","Ectopic ACTH Syndrome",[26,27,28,30,31],"CRN04894","atumelnant","RECRUITING","2026-06-02",{"date":35,"type":36},"2026-06-04","ACTUAL",{"date":38,"type":36},"2023-10-12",{"date":40,"type":19},"2026-10",{"name":42,"class":43},"Crinetics Pharmaceuticals Inc.","INDUSTRY",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":52,"sex":16,"minAge":17,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":20,"phases":56,"briefSummary":57,"conditions":58,"keywords":59,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":44},"100564934","phase-2-desmopressin-stimulation-test-performance-in-acth-dependent-cushing-syndrome-100564934","NCT06635629","Desmopressin Stimulation Test Performance in ACTH-Dependent Cushing Syndrome","Phase II Prospective Evaluation of Desmopressin Stimulation Test Performance in ACTH-dependent Cushing s Syndrome","* INCLUSION CRITERIA:\n\nTo be eligible to participate in this study, an individual must meet all of the following criteria:\n\n* Aged 18-70 years\n* Agreement to adhere to Lifestyle Considerations throughout the study.\n* Evidence of acceptable laboratory testing results within four weeks of the first test day, as shown by medical record review:\n\n  * Hematocrit at entry \\>=33 %\n  * Plasma sodium 136-145 mmol\u002FL (unless taking a drug that can cause hyponatremia, see below) eGFR \\>=60 ml\u002Fmin\u002F1.73 sq.m, calculated based on serum creatinine\n* For subjects taking any drug that could worsen hyponatremia, a normal plasma sodium (136-145 mmol\u002FL) must have been obtained within seven days of the first test day.\n\nIn addition, an individual must meet all the criteria listed for their diagnostic group below, based on medical record review:\n\nA. Patients with possible ACTH-dependent Cushing Syndrome (where the results of further work up will classify the patient as having CD, EAS or pseudo-CS):\n\n1. A. Hypercortisolemia as evidenced by physician note or laboratory report: at least one screening modality (1 mg dexamethasone suppression test, 24-hour urinary free cortisol (UFC), bedtime or late night (2200h - 2359h) salivary or serum cortisol) within 4 weeks of screening. In patients suspected to have cyclic CS any previous abnormal result will suffice.\n2. A. Normal or increased plasma ACTH (\\>20 pg\u002FmL) as evidenced by physician note or laboratory report.\n\nB. Patients with recurrent ACTH-dependent Cushing Syndrome (previous CD or EAS):\n\n1B. Evidence of previous remission of CD or EAS after resection of a causative pituitary or ectopic tumor, evidence of current ACTH-dependent hypercortisolism, and willingness to undergo repeat surgery.\n\nC. Healthy volunteers:\n\nC1. In good general health as evidenced by medical history and physical examination; and in a stable state of health without ongoing acute\u002Ftemporary illness per the clinical judgement of the investigator.\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study, based on medical record review (possible Cushing syndrome patients) or a screening visit (healthy volunteers).\n\n1. Inability to comply with all study procedures and visits\n2. Inability of subject to understand or to sign a written informed consent document.\n3. Known allergy\u002Fhypersensitivity to desmopressin.\n4. Pregnancy or lactation, due to alterations in measured serum cortisol and lack of data on desmopressin safety.\n5. A history of angina, significant coronary artery disease, congestive heart failure, or syndrome of inappropriate antidiuretic hormone secretion (SIADH), due to risk of fluid overload and\u002For hyponatremia.\n6. Uncontrolled hypertension (blood pressure \\>150\u002F95 mmHg) at screening and before desmopressin administration, due to risk of further increase if fluid overload occurs\n7. Any condition that in the opinion of the Investigator would jeopardize the participant s appropriate participation in this study.\n8. Current daily use of any of the following medications:\n\n   * Drug used for the stimulation tests: Desmopressin.\n   * Drugs that can suppress ACTH and cortisol test responses: Systemic glucocorticoids, including inhaled or topical formulations.\n   * Vasopressors: phenylephrine, dopamine and vasopressin.\n   * Drugs that interfere with desmopressin duration of action or potency: carbamazepine, lamotrigine, tolvaptan\n9. Strong inducers of CYP3A4 (e.g. barbiturates, phenytoin, rifampin, rifabutin, rifapentine, carbamazepine, eslicarbazepine, primidone, cenobamate, Modafinil). Use of St John's wort or nafcillin within 14 days.\n10. Initiation or dose increase within the past 14 days of drugs that can worsen hyponatremia: non-steroidal anti-inflammatory drugs (NSAIDs), loop diuretics (bumetanide, ethacrynic acid, furosemide, torsemide), chlorpromazine, chlorpropamide, cisplatin, monoamine oxidase inhibitors (MAOI), opiate agonists, oxybutynin, selective serotonin reuptake inhibitors (SSRI), vincristine, tricyclic antidepressants (TCAs)\n11. Chronic enhanced hydration (estimated as \\>4 liters) to supplement mealtime fluid intake.\n12. Any contraindication to intravenous catheter use.\n13. Previous participation in this protocol.\n14. History of hemophilia of any type.\n15. Any hematology or chemistry screening laboratory value drawn at screening that the Investigator determines is clinically significant for exclusion.\n\nCondition-specific exclusions will also apply to each subject group as follows:\n\nA.Patients with possible ACTH-dependent Cushing Syndrome:\n\n1. A. Use of medications that block glucocorticoid production (ketoconazole, levoketoconazole, metyrapone, osilodrostat) within the past two weeks, if normal cortisol is achieved. If hypercortisolism persists despite the use of these medications, as evidenced by an elevated 24-hour urinary free cortisol (UFC) or late night (2200h - 2359h) salivary or serum cortisol within two weeks of the first desmopressin test, the medication(s) may be continued until 48 hours before the first desmopressin test.\n2. A. Use of the adrenolytic mitotane at any point, due to its prolonged half-life.\n3. A. Use of medications that block glucocorticoid action or ACTH release within the past two weeks - mifepristone, cabergoline, octreotide (subcutaneous), pasireotide (subcutaneous), megestrol acetate, other synthetic glucocorticoids (except for topical or inhaled agents and single doses of oral dexamethasone for diagnostic testing within the past 48 hours)\n4. A. Use of intramuscular long-acting forms of octreotide or pasireotide within the past 4 months.\n5. A. Treatment of diabetes insipidus.\n\nB. Healthy volunteers:\n\n1. B. Use of oral, injectable, or inhaled glucocorticoids (unless intermittent, for symptomatic asthma) within the last year. Use of topical non-hydrocortisone containing potent glucocorticoids on more than 36 square inches in the last six months.\n2. B. Hemoglobin A1c \\>= 6.5% on screening labs.",true,"70 Years",{"count":55,"type":19},140,[23],"Background:\n\nCushing syndrome (CS) is a set of diseases that develop when the body produces too much adrenocorticotropic hormone (ACTH). ACTH stimulates the production of a hormone called cortisol. Excess cortisol can cause serious issues, such as diabetes, high blood pressure, weight gain, and mood changes. Diagnosing CS early can be difficult. One test used to diagnose CS, the desmopressin (Desmo) stimulation test (DesmoST), has not been studied in enough people to know how accurate it is.\n\nObjective:\n\nTo find ways to improve the DesmoST. Researchers especially want to learn more about how well the DesmoST identifies people with specific ACTH CSs: Cushing disease (CD) and ectopic ACTH syndrome (EAS).\n\nEligibility:\n\nPeople aged 18 to 70 years who have or may have CS, especially CD or EAS. Healthy volunteers are also needed.\n\nDesign:\n\nParticipants with CS will have 3 DesmoSTs at least 48 hours apart. The procedure for each is as follows:\n\nThey will limit their fluid intake the day before each test. They will have nothing to eat or drink for 12 hours before the test.\n\nFor 1 of the tests, they will take a pill that contains a hormone (dexamethasone). They will take it around 11 pm the day before the test.\n\nDesmo is given through a tube attached to a needle inserted into a vein.\n\nBlood will be drawn a total of 6 times before and after the desmo is given.\n\nHealthy volunteers will have 4 DesmoSTs. These will be 2 to 14 days apart.\n\nAll participants will have follow-up visits 3 to 5 days after each test. These visits may be by phone.",[26],[60],"desmopressin, Cushing syndrome, diagnosis","2026-05-09",{"date":63,"type":36},"2026-05-12",{"date":65,"type":36},"2024-12-12",{"date":67,"type":19},"2029-01-01",{"name":69,"class":70},"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","NIH",{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":78,"enrollmentInfo":79,"targetDuration":4,"studyType":81,"phases":4,"briefSummary":82,"conditions":83,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":44},"100107943","adrenal-tumors---pathogenesis-and-therapy-100107943","NCT00669266","Adrenal Tumors - Pathogenesis and Therapy","Investigation of the Tumorigenesis of Adrenal Tumors and Evaluation of New Therapeutic Options - Untersuchungen Zur Tumorgenese Von Nebennierentumoren Und Evaluation Neuer Therapieoptionen","Inclusion Criteria:\n\n* adrenal tumor detected by imaging\n\nExclusion Criteria:","100 Years",{"count":80,"type":19},500,"OBSERVATIONAL","The pathogenesis of adrenal tumors is still not fully elucidated and the treatment options for malignant tumors are poor. The current study investigates different aspects of the pathogenesis of adrenal tumors and evaluates different therapeutic options in patients with adrenocortical carcinoma.",[84,85,26,86,87],"Adrenal Tumors","Adrenocortical Carcinoma","Conn Syndrome","Pheochromocytoma","2026-05-01",{"date":90,"type":36},"2026-05-07",{"date":92,"type":36},"2002-09",{"date":94,"type":19},"2032-12",{"name":96,"class":97},"University of Wuerzburg","OTHER",{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":16,"minAge":105,"maxAge":106,"enrollmentInfo":107,"targetDuration":4,"studyType":20,"phases":109,"briefSummary":110,"conditions":111,"keywords":112,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":129},"100340160","phase-2-pharmacokinetic-pk-pharmacodynamic-pd-and-tolerability-of-osilodrostat-in-pediatric-patients-with-cushings-syndrome-100340160","NCT03708900","Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Syndrome","A Phase II, Multicenter, Open-label, Non-comparative Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Tolerability of Osilodrostat in Children and Adolescent Patients With Cushing's Syndrome","Inclusion criteria\n\n1. Male and female children and adolescents from 2 to \\\u003C 18 years of age with Cushing's syndrome of endogenous origin: Who have failed surgery (or) who are awaiting surgery (or) for whom surgery is not an immediate option. For patients who are awaiting surgery, the study treatment could be less than 12 weeks.\n2. Patients must weigh \\> 10 kg.\n3. The diagnosis of Cushing's syndrome must be confirmed by each of the following:\n\n3a) The clinical criterion of decreasing growth percentiles with increasing weight (as evidenced by the presence of a contrast in height and BMI SD scores, for example a SDS \\\u003C 0 and BMI SDS \\> 0, or a strong clinical suspicion of Cushing's syndrome, such as photographic evidence of a change in facial appearance); 3b) Abnormal low-dose (0.5 mg Q6h x 48 hours, or overnight 15mcg\u002Fkg \\[max 1 mg\\]) dexamethasone suppression test, defined as plasma cortisol levels \\> 1.8 mcg\u002Fdl, at time point 48 hours (0.5 mg Q6h x 48 hours) or 9 to 12 hours (overnight 15mcg\u002Fkg \\[max 1 mg\\]) after the first dose of dexamethasone; (OR) Midnight serum cortisol levels \\> ULN, assessed while the patient is sleeping and after pre-cannulation (OR) two samples of late-night salivary cortisol greater than ULN for the assay. 3c)Two 24-hour urinary free cortisol values \\> 1.3 x ULN;\n\n4\\. Able to swallow study drug tablets (not crushed or split) or the content of the capsules mixed with water.\n\n5\\. Parents or legal guardians able to provide consent\u002Fassent.\n\nExclusion Criteria\n\n1. Patients with macroadenoma complicated by compressive symptoms (requiring urgent surgical intervention) or at high risk for compressive symptoms due to mass effect of tumor (concern of corticotroph tumor progression).\n2. Insufficient washout period from any other medication used to lower cortisol levels (5 half-lives of any drug).\n3. Use of other investigational drugs at the time of enrollment, or within 30 days, or prior to completion of a wash-out duration that is at least 5 half- lives of the drug, at the time of enrollment, whichever is longer. Local regulations may require a longer wash-out period or specify other limitations for participation in an investigational trial, in which case they will be applicable as well.\n4. History of hypersensitivity to drugs of the same or similar chemical classes as osilodrostat.\n5. History of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases.\n6. Patients with moderate to severe renal impairment (estimated GFR \\\u003C 60 mL\u002Fmin by the Creatinine-based \"Bedside Schwartz\" equation).\n7. Patients with serum ALT and\u002For AST \\> 3 x ULN, or total bilirubin \\> 1.5 x ULN.\n8. History of thrombosis.\n9. Patients with risk factors for QTc prolongation or Torsade de Pointes, including: 9a) patients with a baseline QTcF \\> 450 ms 9b) personal or family history of long QT syndrome 9c) concomitant medications known to prolong the QT interval 9d) patients with hypokalemia, hypocalcaemia, or hypomagnesaemia, if not corrected before pre-dose Day 0. In case of uncorrected hypokalemia (\\\u003C3.5 mEq\u002FL), the screening period may be used to correct hypokalemia prior to starting study drug. Use of potassium supplements and\u002For mineralocorticoid antagonists is permitted during the study. 9e) Patients with a history of significant cardiovascular disease (based on the opinion of the investigator) such as: structural cardiovascular abnormalities, arrhythmia,\n10. Hypertensive patients with uncontrolled blood pressure defined as SBP \\> 150 and\u002For DBP \\> 100 or not optimally treated for hypertension as judged by the investigator.\n11. Patients who have undergone any major surgery within 1 month.\n12. Patients who have undergone trans-sphenoidal pituitary surgery within 6 weeks prior to screening are not eligible, unless they have clear evidence of persistent hypercortisolism or persistent biochemical changes consistent with Cushing's syndrome.\n13. Use of or anticipated use of systemic glucocorticoid medications 1 month prior to screening.\n14. Uncontrolled hypothyroidism as evidenced by Free T4 \\\u003C 0.8 ng\u002Fdl.\n15. Uncontrolled hyper thyroidism.\n16. Diabetic patients with poorly controlled diabetes as evidenced by HbA1c \\> 8.5 % or not optimally treated for diabetes mellitus as judged by the investigator.\n17. Positive pregnancy test in females of childbearing potential.\n18. Female patients of childbearing potential who do not agree to use highly effective birth control methods .\n19. Pregnant or nursing (lactating) women.\n20. Any medical condition that would, in the investigator's judgment, prevent the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures. Any severe, acute, or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study treatment administration or that may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for the study.\n21. Use of concomitant prohibited medications","2 Years","17 Years",{"count":108,"type":19},12,[23],"Multicenter, open-label, non-comparative study to evaluate the pharmacokinetics, pharmacodynamics, and tolerability of osilodrostat in children and adolescent patients with Cushing's syndrome.",[26],[113,114,115,116,117,118,119],"Cushing's syndrome (CS)","LCI699","osilodrostat","Pituitary Gland","Adrenocorticotropic Hormone (ACTH)","Urinary Free Cortisol (UFC)","mean Urinary Free Cortisol (mUFC)","2026-03-26",{"date":122,"type":36},"2026-03-27",{"date":124,"type":36},"2021-04-28",{"date":126,"type":19},"2027-07-21",{"name":128,"class":43},"RECORDATI GROUP",15,{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":4,"eligibilityCriteria":136,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":137,"targetDuration":139,"studyType":81,"phases":4,"briefSummary":140,"conditions":141,"keywords":166,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":44},"100560175","institutional-registry-of-rare-diseases-100560175","NCT06573723","Institutional Registry of Rare Diseases","Institutional Registries of Rare Diseases at Hospital Italiano de Buenos Aires (HIBA)","Inclusion Criteria:\n\n* Clinical and\u002For molecular diagnosis of any of the following rare diseases: Amyloidosis, Sarcoidosis, Phacomatosis, Pheochromocytoma, Paraganglioma, Von Hippel-Lindau Disease, Immunoglobulin G4-Related Disease, Demyelinating Diseases, Inborn Errors of Metabolism, Eosinophilic Gastrointestinal Disorders, Hypertrophic Cardiomyopathy, Gaucher Disease, Congenital Adrenal Hyperplasia, Hereditary Angioedema, Pulmonary Hypertension, Wilson Disease, Vascular Anomalies, Mastocytosis, Multiple Endocrine Neoplasia, Inflammatory Bowel Diseases, Prader-Willi Syndrome, Hirschsprung Disease, or Cushing Syndrome.\n* Must be followed at Hospital Italiano de Buenos Aires.\n\nExclusion Criteria:\n\n\\- Refusal to participate in the study or in the informed consent process.",{"count":138,"type":19},380,"10 Years","The goal of this observational study is to create a single macro registry system with data collection on common clinical features, grouping the different rare diseases (RD).\n\nMoreover, the specific goals are to generate an alert system for possible cases of RD with data from the electronic medical record, to describe the occurrence of RD in the evaluated population, to characterize the population, to describe patterns of diagnosis and treatment of RD present at the time, and to explore patient-reported outcomes.",[142,143,144,145,87,146,147,148,149,150,151,152,153,154,155,156,157,158,159,160,161,162,163,26,164,165],"Rare Diseases","Amyloidosis","Sarcoidosis","Phacomatosis","Paraganglioma","Von Hippel-Lindau Disease","Immunoglobulin G4-Related Disease","Demyelinating Diseases","Inborn Errors of Metabolism","Eosinophilic Gastrointestinal Disorders","Hypertrophic Cardiomyopathy","Gaucher Disease","Congenital Adrenal Hyperplasia","Hereditary Angioedema","Pulmonary Hypertension","Wilson Disease","Vascular Anomalies","Mastocytosis","Multiple Endocrine Neoplasia","Inflammatory Bowel Diseases","Prader-Willi Syndrome","Hirschsprung Disease","HHT","Hemorrhagic Hereditary Telangiectasia",[167,168,169,145,170,171,147,148,149,150,151,152,153,154,155,156,157,158,159,160,161,162,163,26,165],"rare diseases","amyloidosis","sarcoidosis","pheochromocytoma","paraganglioma","2026-01-12",{"date":174,"type":36},"2026-01-14",{"date":176,"type":36},"2024-07-01",{"date":178,"type":19},"2034-12-31",{"name":180,"class":97},"Hospital Italiano de Buenos Aires",{"id":182,"slug":183,"hasResults":11,"nctId":184,"briefTitle":185,"officialTitle":186,"acronym":187,"eligibilityCriteria":188,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":189,"targetDuration":4,"studyType":20,"phases":191,"briefSummary":193,"conditions":194,"keywords":197,"overallStatus":201,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":203,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":4},"100611944","phase-4-osilodrostat-in-patients-with-hypertension-caused-by-hypercortisolaemia-due-to-cushings-syndrome-100611944","NCT07247162","Osilodrostat in Patients With Hypertension Caused by Hypercortisolaemia Due to Cushing's Syndrome","A Double-blind, Randomised, 30-week Placebo-controlled Phase IV Study to Assess the Efficacy and Safety of Osilodrostat in Patients With Hypertension Caused by Hypercortisolaemia Due to Cushing's Syndrome","LINC CARE","Inclusion Criteria:\n\n1. Male or female ≥ 18 years of age\n2. Able to provide and have provided signed written informed consent prior to study participation\n3. Diagnosis of endogenous Cushing's Syndrome\n4. mUFC values from two 24h urinary collections \\> ULN and ≤ 2x ULN\n5. Participants with uncontrolled hypertension on stable doses of BP lowering medications (for at least 4 weeks); qualifying BP measurements by ABPM taken prior to randomisation defined as: Average of 24h ABPM SBP ≥ 135 or DBP ≥ 85 mmHg\n6. Participants under glucocorticoid replacement therapy can be recruited only if this therapy has been already stopped for at least seven days or 5 half-lives prior to screening, whichever was longer\n7. Not taking any drug therapy for CS. The following minimum periods without these medications need to be completed before baseline assessments:\n\n   1. Steroidogenesis inhibitors (e.g. ketoconazole, metyrapone): 1 week\n   2. Mifepristone: 3 weeks\n   3. SC Pasireotide: 1 week\n   4. Pasireotide LAR: 3 months\n   5. Cabergoline: 4 weeks\n8. Able to take oral medication and be willing to comply with the requirements of the study\n\nExclusion Criteria:\n\n1. Previously treated with osilodrostat less than 12 weeks prior to start of screening\n2. Known hypersensitivity to osilodrostat\n3. Presence of any severe and\u002For uncontrolled medical condition or other conditions that could affect participation in the study\n4. Participants who are scheduled for a surgery to treat CS within 32 weeks of randomisation to the study drug\n5. Presence of a known \"long term\" history of both hypertension and diabetes (defined as both hypertension and diabetes diagnosed \\>10 years prior to the initial diagnosis of endogenous CS)\n6. History of cyclic Cushing's Syndrome with fluctuating clinical manifestations\n7. Participants with pseudo-CS\n8. Participants with compression of the optic chiasm due to a macroadenoma or participants at high risk of compression of the optic chiasm (tumour within 2 mm of optic chiasm)\n9. Pituitary radiation therapy within 3 years of screening\n10. Ectopic ACTH syndrome or adrenocortical carcinoma with a life expectancy of \\\u003C3 years or receiving chemotherapy\n11. Having received prior mitotane treatment\n12. Participants who are shift workers or have conditions that can affect the measurement of late night salivary cortisol (LNSC) or the LDDST\n13. Poorly controlled diabetes mellitus with a baseline HbA1c \\> 10.5%\n14. Poorly controlled BP defined as: Average SBP ≥ 170 or average DBP ≥ 110 mmHg as measured by the 24h ABPM\n15. Participants who are hypothyroid and not on adequate replacement therapy\n16. History of major surgery\u002Fsurgical therapy for any cause within 1 month before entering the study.\n17. Presence of bradycardia and\u002For QT-related exclusion criteria\n18. Total bilirubin \\> 1.5 x ULN and ALT or AST \\> 3 x ULN\n19. Participation in any clinical investigation within 4 weeks prior to screening or longer if required by local regulation (Use of an investigational drug within 1 month prior to dosing)\n20. Occurrence of any significant acute illness within the three weeks prior to dosing\u002Frandomisation\n21. Female participants who are pregnant, intending to become pregnant or breastfeed during the study or lactating, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test\n22. Women of childbearing potential (WOCBP) who are unwilling to use highly effective contraception methods\n23. Potentially unreliable or vulnerable participants (e.g. person kept in detention) and those judged by the Investigator to be unsuitable for the study",{"count":190,"type":19},63,[192],"PHASE4","Osilodrostat has proven to be a safe and efficacious treatment for patients with CS. Demonstrating normalisation of hypercortisolaemia and in patients with hypertension and\u002For dysglycaemia clinically relevant and statistically significant reductions in blood pressure and glycaemia. This study aims at providing additional evidence on the safety, efficacy and appropriate dosing of osilodrostat in patients with CS, who have hypertension.",[195,196,26],"Hypertension","Hypercortisolemia",[115,198,199,200],"hypertension","hypercolesterolaemia","cushing's syndrome","NOT_YET_RECRUITING","2025-12-03",{"date":204,"type":36},"2025-12-10",{"date":206,"type":19},"2026-08",{"date":208,"type":19},"2028-07",{"name":128,"class":43},{"id":211,"slug":212,"hasResults":11,"nctId":213,"briefTitle":214,"officialTitle":215,"acronym":4,"eligibilityCriteria":216,"healthyVolunteers":11,"sex":16,"minAge":217,"maxAge":4,"enrollmentInfo":218,"targetDuration":4,"studyType":81,"phases":4,"briefSummary":220,"conditions":221,"keywords":223,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":227,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":234},"100313771","collecting-information-about-treatment-results-for-patients-with-cushings-syndrome-100313771","NCT03364803","Collecting Information About Treatment Results for Patients With Cushing's Syndrome","Treatment Outcomes for Patients With Cushing's Syndrome: a Prospective Data Collection Study","Inclusion Criteria:\n\n* Age 14 or older\n* Active or treated overt Cushing's (due to pituitary, ectopic, or adrenal tumor), mild adrenal Cushing's syndrome (MACS), or a silent corticotroph tumor\n* The diagnosis of CS or MACS will be made by the PI, based on the below Endocrine Society guidelines, the patient's clinical presentation, and the PI's judgment.\n\n  * Diagnostic criteria for ACTH-dependent Cushing's are according to the Endocrine Society and European Society of Endocrinology guidelines and include: Elevated 24-hour urinary free cortisol (UFC), normal or elevated plasma ACTH, elevated midnight salivary cortisol levels, or classic dexamethasone suppression testing for CD (morning cortisol \\> 5 ug\u002FdL after 1 mg overnight of classic 2-day low dose test) and a pituitary lesion on MRI (in the case of pituitary Cushing's). If patient does not have any of these results, pathology of ACTH tumor may confirm presence of disease.\n  * Diagnostic criterion for MACS is according to the European Society of Endocrinology guidelines: Classic dexamethasone suppression testing for CS (morning cortisol \\>1.8 µg\u002FdL after 1 mg overnight) and the presence of an adrenal adenoma.\n* Silent corticotroph tumors will be defined by surgical pathology demonstrating positivity for ACTH, in the absence of clinical and biochemical features of Cushing's syndrome.\n* In lieu of MRI, surgical, or laboratory reports, physician's assessment note including mention of results will also be used as source for eligibility purposes.\n\nExclusion Criteria:\n\n* Patients with a diagnosis of iatrogenic Cushing's.","14 Years",{"count":219,"type":19},300,"The purpose of this study is to follow participants with Cushing's syndrome during the course of their routine care and to form a data registry to study long term participant outcomes.",[222,26,27],"Cushing's Disease",[26,222,27,224,225],"17-592","Memorial Sloan Kettering Cancer Center","2025-10-22",{"date":228,"type":36},"2025-10-23",{"date":230,"type":36},"2017-11-28",{"date":232,"type":19},"2026-11-28",{"name":225,"class":97},7,{"id":236,"slug":237,"hasResults":11,"nctId":238,"briefTitle":239,"officialTitle":240,"acronym":4,"eligibilityCriteria":241,"healthyVolunteers":52,"sex":16,"minAge":17,"maxAge":242,"enrollmentInfo":243,"targetDuration":4,"studyType":81,"phases":4,"briefSummary":245,"conditions":246,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":250,"startDateStruct":252,"completionDateStruct":254,"leadSponsor":256,"locationsCount":44},"100605868","establishment-and-clinical-application-of-reference-intervals-of-salivary-cortisol-100605868","NCT07168122","Establishment and Clinical Application of Reference Intervals of Salivary Cortisol","Study for Reference Intervals and Optimal Cut-offs for Salivary Cortisol","Healthy Volunteers:\n\nInclusion Criteria:\n\n1. Age ≥ 18 and ≤ 60 years old;\n2. Body mass index (BMI) ≥ 18.5 and ≤ 24.9 kg\\*m\\^-2;\n3. No previous history of chronic diseases such as hyperglycemia, hypertension, dyslipidemia, coronary heart disease and stroke;\n4. Normal glucose regulation, defined as: fasting blood-glucose \\\u003C 5.6 mmol\u002FL, 2-hour blood-glucose after glucose load \\\u003C 7.8 mmol\u002FL, and glycated hemoglobin (HbA1c) \\\u003C 5.7%.\n\nExclusion Criteria:\n\n1. Liver or kidney dysfunction, alanine aminotransferase (ALT) or aspartate aminotransferase (AST) or direct bilirubin higher than 1.5 times the upper limit of normal, or serum creatinine \\>115 μmol\u002FL;\n2. Pregnancy or lactation women, or people with cancer or mental illness;\n3. Factors affecting cortisol levels, including hypothalamus-pituitary-adrenal axis disease, autoimmune disease (systemic lupus erythematosus, rheumatoid arthritis, etc.), diagnosed mental disease, Alzheimer's disease, alcoholism (alcohol \\> 60 g\u002Fd for male, \\>40 g\u002Fd for women) and corticosteroid therapy in the past 3 months (females with contraceptives or estrogen);\n4. Factors affecting saliva collection, such as serious oral problems (oral ulcers, gingival bleeding);\n5. Night shift workers, who are awake from 11:00 PM to 7:00 AM;\n6. Acute infection (body temperature ≥ 37.3 ℃ or C-reactive protein \\> 50 mg\u002FL).\n\nCases:\n\nInclusion Criteria:\n\n1. Aged 18 to 80 years old;\n2. Patients with suspected Cushing's syndrome or adrenal insufficiency.\n\nExclusion Criteria:\n\n1. Corticosteroid therapy within the last 6 weeks;\n2. Acute infection;\n3. Severe oral conditions;\n4. Severe liver and kidney dysfunction;\n5. Alcoholism, depression, or other psychiatric disorders.","80 Years",{"count":244,"type":19},220,"The goal of this observational study is to establish the normal reference intervals of salivary cortisol and optimal cut-offs for Cushing's sydrome and adrenal insufficiency.",[247,26,248],"Healthy Adult","Adrenal Insufficiency","2025-09-04",{"date":251,"type":36},"2025-09-11",{"date":253,"type":19},"2025-09-01",{"date":255,"type":19},"2027-12-31",{"name":257,"class":97},"Shanghai 6th People's Hospital",{"id":259,"slug":260,"hasResults":11,"nctId":261,"briefTitle":262,"officialTitle":262,"acronym":4,"eligibilityCriteria":263,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":264,"targetDuration":4,"studyType":81,"phases":4,"briefSummary":266,"conditions":267,"keywords":268,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":273,"lastUpdatePostDateStruct":274,"startDateStruct":276,"completionDateStruct":278,"leadSponsor":280,"locationsCount":44},"100404201","recovery-from-cushing-syndrome-and-mild-autonomous-cortisol-secretion-macs-100404201","NCT04543253","Recovery From Cushing Syndrome and Mild Autonomous Cortisol Secretion (MACS)","Inclusion Criteria:\n\n1. age 18 and above,\n2. new diagnosis of CS of any of the three subtypes (pituitary, adrenal or ectopic CS), and MACS,\n3. planning for a curative surgery\n4. ability to provide informed consent.\n\nExclusion Criteria:\n\n1. systemic supraphysiological GC for any reason within 1 month of enrollment, for more than 2 weeks,\n2. inability to provide informed consent",{"count":265,"type":19},700,"Cushing syndrome (CS) is an endocrine disorder caused by chronic exposure to glucocorticoid (GC) excess. Endogenous CS has an estimated incidence of 0.2 to 5.0 cases per million per year and prevalence of 39 to 79 cases per million in various populations. CS usually affects young women, with a median age at diagnosis of 41.4 with a female-to-male ratio of 3:1. Following a curative surgery for CS, patients develop adrenal insufficiency and require GC replacement postoperatively until the hypothalamic-pituitary-adrenal (HPA) axis recovery occurs. Factors, such as age, gender, BMI, subtypes of CS, duration of symptoms, clinical and biochemical severity and postoperative GC dose have been reported to affect the HPA recovery in small retrospective studies. Glucocorticoid withdrawal syndrome (GWS) is a withdrawal reaction due to decrease in supraphysiological GC concentrations, which occurs after a successful surgery of CS. Glucocorticoid withdrawal syndrome (GWS) is under-recognized entity in patients undergoing curative surgery for endogenous Cushing syndrome.\n\nIn this study we aim to determine pre- and post-surgical predictors of the duration and severity of glucocorticoid withdrawal in patients undergoing a curative surgery for cortisol excess and assess the effect of MUSE intervention on GWS severity in patients undergoing curative surgery for CS as compared to standard of care.",[26],[269,270,271,272],"Hypercortisolism","Cushing syndrome","Cushing disease","Pituitary","2025-08-26",{"date":275,"type":36},"2025-09-03",{"date":277,"type":36},"2019-07-25",{"date":279,"type":19},"2030-12",{"name":281,"class":97},"Mayo Clinic",{"id":283,"slug":284,"hasResults":11,"nctId":285,"briefTitle":286,"officialTitle":286,"acronym":4,"eligibilityCriteria":287,"healthyVolunteers":52,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":288,"targetDuration":4,"studyType":20,"phases":290,"briefSummary":292,"conditions":293,"keywords":295,"overallStatus":201,"whyStopped":4,"lastUpdateSubmitDate":301,"lastUpdatePostDateStruct":302,"startDateStruct":304,"completionDateStruct":306,"leadSponsor":308,"locationsCount":44},"100591463","continuous-steroid-monitoring-in-interstitial-fluid-with-wearable-and-nanoparticle-enhanced-biosensors-for-improved-management-of-adrenal-disorders-100591463","NCT06980753","Continuous Steroid Monitoring in Interstitial Fluid With Wearable and Nanoparticle-enhanced Biosensors for Improved Management of Adrenal Disorders","Inclusion Criteria:\n\n* Individuals (males and females) older than 18 years;\n* Patients with primary adrenal insuffiency (cortisol and aldosterone deficiency);\n* Patients with Cushing Syndrome (cortisol excess)\n* Patients with Primary Aldosteronism (aldosterone excess)\n\nExclusion Criteria:\n\n* Use of estrogen-containing oral contraceptive medication within the past 6 weeks;\n* Pregnancy or lactation;\n* Use of oral, inhaled, parenteral, or topical glucocorticoids within the past 30 days.",{"count":289,"type":19},246,[291],"NA","The goal of this project is to provide novel technology that will pave the way from the present single-point (analogue) endocrinology towards continuous cortisol and aldosterone monitoring with full time resolution. Current endocrine practice relies on occasional and often random determination of hormone level or functional tests that require a clinical setting. These measurements include sample extraction and analysis in a clinical laboratory rendering such tests laborious and expensive. Most importantly, through the individual variations of hormone oscillation and spatiotemporal distribution of hormones, infrequent hormone measurements have limited diagnostic and prognostic value as the dynamic changes are not captured and relevant intra-individual variability occurs. A requirement for this vision are sensing solutions capable to track hormone dynamics over prolonged periods at high patient comfort (e.g., at home), as targeted by this research proposal. This project has the overarching goals of (1) establishing dynamic interstitial aldosterone and cortisol monitoring as reliable diagnostic tool for cortisol and aldosterone excess or deficiency, and (2) develop a wearable molecular sensing device to detect them accurately.",[26,294,248],"Primary Aldosteronism",[296,297,298,299,300,270],"Aldosterone","Cortisol","Biossensor","Interstitial fluid","Adrenal insuficiency","2025-05-16",{"date":303,"type":36},"2025-05-20",{"date":305,"type":19},"2025-06-01",{"date":307,"type":19},"2025-12-01",{"name":309,"class":97},"University of Sao Paulo General Hospital",{"id":311,"slug":312,"hasResults":11,"nctId":313,"briefTitle":314,"officialTitle":315,"acronym":316,"eligibilityCriteria":317,"healthyVolunteers":52,"sex":16,"minAge":318,"maxAge":319,"enrollmentInfo":320,"targetDuration":4,"studyType":81,"phases":4,"briefSummary":322,"conditions":323,"keywords":324,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":330,"lastUpdatePostDateStruct":331,"startDateStruct":332,"completionDateStruct":334,"leadSponsor":336,"locationsCount":44},"100590037","modified-desmopressin-mdesmo-using-cold-kit-for-petct-100590037","NCT06962202","Modified Desmopressin (mDesmo) Using Cold-Kit for PET\u002FCT","Modified Desmopressin (Mdesmo Cold-Kit) for PET Imaging to Localize Adrenocorticotropic Hormone (ACTH) Dependent Cushing Syndrome (CS)","Ga-68 mDesmo","Inclusion Criteria:\n\n1. Patients diagnosed with endogenous Cushing's syndrome\n2. Patients in the age group of 5 to 75 years.\n3. Patients willing to give informed consent.\n\nExclusion Criteria:\n\n1. Patient with exogenous exposure to steroids\n2. Ongoing pregnancy\n3. Severe comorbid conditions that may interfere with the study.","5 Years","75 Years",{"count":321,"type":19},100,"The incidence of Cushing syndrome (CS) is 1.2-3.2 cases per million per year, of which adrenocorticotropic Hormone (ACTH)-dependent disease comprises approximately 70-80% of cases. Among these, nearly 90% of ACTH-dependent CS are due to pituitary-dependent CS, known as Cushing disease (CD). The management of ACTH-dependent CS relies on distinguishing Cushing disease (or Corticotropinoma) from ectopic Cushing syndrome (ECS) followed by localization of the tumor in the sella. The diagnosis of CD is very challenging, especially when they are microadenomas (\\\u003C6 mm). Current imaging techniques, such as magnetic resonance imaging (MRI), have limitations in accurately delineating (sensitivity 60%) these tumors. Even if the lesion is detected inside the pituitary, the functionality of the tumor is questionable, as there can be innocent pituitary tumors which actually are not the cause of Cushing syndrome in a particular case. The diagnosis gets more complex with the fact that 10% of the ECS cases are reported to have an incidental non-functioning pituitary tumor, this can complicate the diagnosis of ECS. Though the localizing accuracy of bilateral inferior petrosal sinus sampling (BIPSS) is 90%, the lateralization (40-70%) of corticotropinoma (whether the lesion is located on the right or left side) based on BIPSS is still questionable. These challenges contribute to the fact that in approximately 30% of cases of CD, the source of ACTH excess remains occult. The lack of information on accurate localization and lateralization of corticotropinoma leads to reduced remission rates after surgery. Therefore, novel approaches to diagnosing Cushing disease are needed.\n\nWe have developed a novel radiopharmaceutical Gallium-68- 1,4,7,10-tetraazacyclododecane-N,N',N',N'-tetraacetic acid-modified desmopressin (68Ga-DOTA-mDesmo) for Positron Emission Tomography\u002FComputed Tomography (PET\u002FCT). This radiopharmaceutical has the potential to selectively target the overexpressed V1b receptors in patients diagnosed with Cushing disease. The clinical studies demonstrated 100% diagnostic accuracy of 68Ga-DOTA-mDesmo PET\u002FCT in delineating corticotropinomas, surpassing the accuracy of CE-MRI and BIPSS, regardless of adenoma size. However, the small sample size and regional patient recruitment may affect the generalizability of the results.\n\nThe project aims to assess the diagnostic sensitivity and specificity of 68Ga-DOTA-mDesmo in a diverse Cushing syndrome population. This will lead to development and validation of a superior, non-invasive diagnostic modality for accurate corticotropinoma delineation, aiding neuro-navigation during surgery and potentially improving treatment outcomes for ACTH-dependent Cushing syndrome.",[26],[325,326,327,328,329],"ACTH","bilateral inferior petrosal sinus sampling","Corticotropinoma","transsphenoidal surgery","PET\u002FCT","2025-05-15",{"date":303,"type":36},{"date":333,"type":36},"2022-08-15",{"date":335,"type":19},"2025-10",{"name":337,"class":97},"Post Graduate Institute of Medical Education and Research, Chandigarh",{"id":339,"slug":340,"hasResults":11,"nctId":341,"briefTitle":342,"officialTitle":343,"acronym":344,"eligibilityCriteria":345,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":346,"targetDuration":348,"studyType":81,"phases":4,"briefSummary":349,"conditions":350,"keywords":351,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":354,"lastUpdatePostDateStruct":355,"startDateStruct":357,"completionDateStruct":359,"leadSponsor":361,"locationsCount":44},"100479326","cushings-syndrome-before-and-after-treatment-correct-100479326","NCT05521529","Cushing's Syndrome Before and After Treatment (CORRECT)","Effects of CORtisol Excess and REmission in Cushing's Syndrome Over Time (CORRECT): A Prospective Non-interventional Cohort Study","CORRECT","Inclusion Criteria:\n\n* New (≤ 2 months) diagnosis of Cushing's syndrome (CS) of endogenous etiology:\n\n  * ACTH-dependent CS\n  * ACTH-independent CS\n* Age \\>18 years\n* Written informed consent\n\nExclusion Criteria:\n\n* Active cancer\n* Iatrogenic or malignant cause of CS such as adrenocortical carcinoma\n* Chronic heart failure (New York Heart Association class IV)\n* Chronic kidney disease Chronic Kidney Disease stage ≥3 (eGFR \\>30 ml\u002Fmin)\n* Liver disease in the form of cirrhosis\n* Deemed unable to complete the study safely by investigator",{"count":347,"type":19},20,"1 Year","The purpose of this study is to prospectively study patients with Cushing's syndrome before and after treatment, with a special emphasis on physical function, quality of life, and circadian rhythms.\n\nThe hypotheses are:\n\n* Cushing's syndrome negatively impacts health-related quality of life (HRQoL) and physical functioning\n* Cushing's syndrome is associated with altered circadian rhythms at the whole body level and in peripheral target tissues.\n* These complications partially reverse following disease control.",[26],[352,353],"Circadian Rhythm","Quality of Life","2025-04-01",{"date":356,"type":36},"2025-04-04",{"date":358,"type":36},"2023-02-16",{"date":360,"type":19},"2032-11",{"name":362,"class":97},"University of Aarhus",{"id":364,"slug":365,"hasResults":11,"nctId":366,"briefTitle":367,"officialTitle":368,"acronym":4,"eligibilityCriteria":369,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":319,"enrollmentInfo":370,"targetDuration":4,"studyType":20,"phases":372,"briefSummary":373,"conditions":374,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":376,"lastUpdatePostDateStruct":377,"startDateStruct":379,"completionDateStruct":381,"leadSponsor":383,"locationsCount":385},"100577665","phase-4-effect-of-metyrapone-on-cardiovascular-risk-factors-in-patients-with-adrenal-incidentalomas-and-cushings-syndrome-100577665","NCT06801249","Effect of Metyrapone on Cardiovascular Risk Factors in Patients With Adrenal Incidentalomas and Cushing's Syndrome","\"Effect of Metyrapone on Cardiovascular Risk Factors in Patients With Adrenal Incidentalomas and Subclinical\u002FMild Cushing's Syndrome","Inclusion Criteria:\n\nInclusion criteria - run-in (phase 1)\n\n* Unilateral or bilateral adrenal nodules with benign features associated with thickening of the adrenal arms \\>5 mm on abdominal CT scan\n* SCS (detected 2 times in the 6 months before run-in) defined by the absence of catabolic signs of Cushing's syndrome in association with any of these 3 conditions:\n\n  * Cortisol levels after dexamethasone 1 mg test \\>50 nmol\u002FL associated with baseline ACTH \\\u003C10 pg\u002FmL\n  * Cortisol levels after dexamethasone 1 mg test \\>50 nmol\u002FL associated with increased nocturnal (11 pm) salivary cortisol\n  * Cortisol levels after dexamethasone 1 mg test \\>138 nmol\u002FL\n* Hypertension (BP ≥140\u002F90 mmHg and\u002For ongoing antihypertensive treatment)\n* Patients who cannot undergo surgery\n* Acquisition of informed consent.\n\nInclusion criteria - randomization (phase 2)\n\n\\- BP \\>100\u002F60 mmHg and \\\u003C130\u002F85 mmHg on antihypertensive therapy (lowest effective dose) within 6-10 months after enrollment.\n\nExclusion Criteria:\n\n* Body mass index ≥40 kg\u002Fm2\n* Pregnant or lactating women; diagnosis of pregnancy will be made by serum β-HCG assay\n* Women of childbearing age using contraceptive measures other than barrier contraception. Barrier contraceptive measures are: o Male or female condom with or without spermicide o Cervical cup, diaphragm or sponges with spermicide o Combination of male condom and cervical cup, diaphragm or sponges with spermicide (dual barrier methods)\n* Treatment with steroids in the last year before enrollment\n* Taking medications known to interfere with Metirapone\n* Known or suspected hypersensitivity to the drug or drug class under study\n* Patients with serious clinical conditions that, in the opinion of the Investigator, contraindicate the patient's participation in the study\n* Patients with primary corticosurrenal insufficiency, impaired adrenal secretion, and severe hypopituitarism\n* Patients with impaired liver function\n* Patients with untreated hypothyroidism or being treated with drugs that have an action on the hypothalamic-pituitary-adrenal axis\n* Patients with hypersensitivity to the active ingredient or any of the excipients listed in section 6.1 of the RCP - Metirapone.",{"count":371,"type":19},50,[192],"Drug interventional, controlled, randomized open-label, parallel-group, multicenter study in patients with bilateral adrenal incidentalomas associated with subclinical Cushing's syndrome",[375,26],"Adrenal Incidentalomas","2025-01-24",{"date":378,"type":36},"2025-01-30",{"date":380,"type":36},"2021-02-23",{"date":382,"type":19},"2025-02-17",{"name":384,"class":97},"IRCCS Azienda Ospedaliero-Universitaria di Bologna",3,{"id":387,"slug":388,"hasResults":11,"nctId":389,"briefTitle":390,"officialTitle":391,"acronym":392,"eligibilityCriteria":393,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":394,"targetDuration":4,"studyType":20,"phases":395,"briefSummary":396,"conditions":397,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":399,"lastUpdatePostDateStruct":400,"startDateStruct":402,"completionDateStruct":404,"leadSponsor":406,"locationsCount":409},"100506947","nac--nafld-and-cushing-100506947","NCT05881005","NAC- NAFLD and Cushing","Prévalence De La Stéato-fibrose Hépatique Dans Le Syndrome De Cushing","NAC","Inclusion Criteria:\n\n* Age \\> 18 years\n* Active Cushing's syndrome\n\nExclusion Criteria:\n\n* Other common causes of chronic liver disease (HBV, HCV, haemochromatosis, alcohol)\n* Contraindication to MRI",{"count":321,"type":19},[291],"Cushing's Syndrome is a rare disease resulting from prolonged exposure to high levels of circulating cortisol. Clinical manifestations are variable but many patients present a metabolic syndrome (abdominal obesity, insulin resistance, dyslipidemia, hypertension). With regard to the liver, experimental data have shown that excess cortisol leads in an increase in lipogenesis and a reduction in the oxidation of fatty acids. This, in association with an accumulation of visceral adipose tissue and deregulation of adipokines, may contribute to the development of hepatic steatosis in animals. However, few data is available in humans with only one study of 50 patients with Cushing's syndrome estimating the prevalence of hepatic steatosis at 20%.\n\nNAFLD (Non-Alcoholic Fatty Liver Disease), is defined as the presence of hepatic steatosis in the absence of secondary causes of intrahepatic fat accumulation. It is a heterogeneous disease ranging from simple liver steatosis, whose prognosis is generally considered to be benign, to inflammation (NASH, Non-Alcoholic Steato-Hepatitis) which may progress to fibrosis, cirrhosis and an increased risk of hepatocellular carcinoma. The prognosis for NAFLD is mainly related to the severity of hepatic fibrosis.\n\nIn Cushing's syndrome, normalization of cortisol production is the most effective strategy to improve co-morbidities associated with hypercortisolism. However, some of these complications, especially the metabolic co morbidities, could not be completely reversible and no data is available about resolution of hepatic steatosis.",[26,398],"Fatty Liver Disease","2024-12-11",{"date":401,"type":36},"2024-12-16",{"date":403,"type":36},"2023-09-28",{"date":405,"type":19},"2027-09-28",{"name":407,"class":408},"University Hospital, Angers","OTHER_GOV",6,{"id":411,"slug":412,"hasResults":11,"nctId":413,"briefTitle":414,"officialTitle":414,"acronym":4,"eligibilityCriteria":415,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":416,"targetDuration":4,"studyType":81,"phases":4,"briefSummary":418,"conditions":419,"keywords":4,"overallStatus":201,"whyStopped":4,"lastUpdateSubmitDate":425,"lastUpdatePostDateStruct":426,"startDateStruct":428,"completionDateStruct":430,"leadSponsor":432,"locationsCount":4},"100541207","neuroendocrine-mechanisms-in-adiposity-an-integrated-approach-to-the-characterization-of-potential-pharmacological-novel-targets-based-on-experimental-and-clinical-models-100541207","NCT06326853","Neuroendocrine Mechanisms in Adiposity: An Integrated Approach to the Characterization of Potential Pharmacological Novel Targets Based on Experimental and Clinical Models","Inclusion Criteria:\n\nObese patients affected and not by hypothalamic-pituitary diseases\n\nExclusion Criteria:\n\n1. Minor subjects;\n2. Pregnant and\u002For breastfeeding women;\n3. Patients suffering from states of primary and\u002For acquired immunodeficiencies, and\u002For serious impairment of general clinical conditions (e.g. metastatic neoplasms; immunosuppressive therapies; worsening\u002Freacerbated\u002Fcompensated chronic pathologies);\n4. Patients unable to understand and sign the Informed Consent.",{"count":417,"type":19},200,"The goal of this observational study is to evaluate, retrospectively and prospectively, the effect of different hormonal and neuropeptide dysfunctions on the body composition of patients suffering from hypothalamic-pituitary pathologies, and to evaluate the potential beneficial effect of surgical and medical treatments with agonists and antagonists of hypothalamic neuropeptides, currently available, on the development and treatment of adiposity and negative cross-talk between adiposity and muscle\u002Fbone tissue",[420,421,422,26,423,424],"Endocrine Disorders","Adiposity","Pituitary Adenoma","Acromegaly","Hypopituitarism","2024-06-10",{"date":427,"type":36},"2024-06-11",{"date":429,"type":19},"2024-07",{"date":431,"type":19},"2026-12",{"name":433,"class":97},"IRCCS San Raffaele",{"id":435,"slug":436,"hasResults":11,"nctId":437,"briefTitle":438,"officialTitle":439,"acronym":4,"eligibilityCriteria":440,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":53,"enrollmentInfo":441,"targetDuration":4,"studyType":20,"phases":442,"briefSummary":443,"conditions":444,"keywords":446,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":450,"lastUpdatePostDateStruct":451,"startDateStruct":453,"completionDateStruct":455,"leadSponsor":457,"locationsCount":44},"100535351","a-single-center-randomized-controlled-study-on-the-promotion-of-rapid-recovery-100535351","NCT06250699","A Single Center Randomized Controlled Study on the Promotion of Rapid Recovery","A Single Center Randomized Controlled Study on the Promotion of Rapid Recovery Through Tubeless Laparoscopic Adrenalectomy","Inclusion Criteria:\n\n1. According to the 2022 edition of the Chinese Guidelines for Diagnosis and Treatment of Urological Diseases, patients who meet the surgical indications\n2. The patient has signed an informed consent form before joining the clinical trial, and the age at the time of signing the informed consent form is 18-70 years old.\n\nExclusion Criteria:\n\n1. Patients with complications that seriously affect treatment or quality of life\n2. The patient has any physical condition that the researcher believes will affect the clinical status\n3. Patients who have placed vascular stents such as heart and cerebrovascular stents within the past year\n4. Pregnant or lactating patients",{"count":417,"type":19},[291],"The goal of this clinical trial is to exploring the role of tubeless after adrenalectomy surgery. The main questions it aims to answer are:\n\n1. The safety of tubeless laparoscopic adrenalectomy；\n2. The role of tubeless therapy in rapid recovery after adrenalectomy surgery Participants will be randomly divided into two groups: the non drainage group and the drainage group after laparoscopic adrenal surgery, and their pain, first time out of bed, and intestinal recovery time will be observed.",[445,294,26],"Nonfunctional Adrenal Cortex Adenoma",[447,448,449],"tubeless","laparoscopic adrenalectomy","rapid recovery","2024-02-08",{"date":452,"type":36},"2024-02-13",{"date":454,"type":36},"2024-01-03",{"date":456,"type":19},"2027-06-30",{"name":458,"class":97},"Zhe Meng",{"id":460,"slug":461,"hasResults":11,"nctId":462,"briefTitle":463,"officialTitle":463,"acronym":464,"eligibilityCriteria":465,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":466,"targetDuration":4,"studyType":20,"phases":468,"briefSummary":469,"conditions":470,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":472,"lastUpdatePostDateStruct":473,"startDateStruct":475,"completionDateStruct":476,"leadSponsor":478,"locationsCount":44},"100509299","evaluation-of-the-severity-of-hepatic-fibrosis-by-magnetic-resonance-elastography-in-the-diagnosis-of-endogenous-hypercorticism-100509299","NCT05911620","Evaluation of the Severity of Hepatic Fibrosis by Magnetic Resonance Elastography in the Diagnosis of Endogenous Hypercorticism","HEPACORT","Inclusion Criteria:\n\n* age ≥ 18 years old;\n* Person affiliated to a social security scheme or beneficiary of such a scheme;\n* Person having received complete information on the organization of the research and having signed informed consent;\n* Person having carried out a preliminary clinical examination adapted to the research.\n* Patients with Cushing's syndrome (for the Cushing's Syndrome group)\n* Patients with possible Cushing's syndrome (for the suspected Cushing's Syndrome group) defined as response to the dexamethasone supression test with 1 mg of Dexamethasone, with a plasma cortisol assay at 8 am between 18 and 50 µg\u002FL carried out in the 3 months preceding ;\n* Patients with metabolic syndrome (for the metabolic syndrome group)\n\nExclusion Criteria:\n\n* Person having taken corticosteroid therapy for more than 3 months during the 2 years preceding inclusion;\n* Person having received corticosteroid therapy of shorter duration with discontinuation less than one month before inclusion;\n* Person having taken anticortisolic treatment for more than 3 months during the 2 years preceding inclusion;\n* Person with chronic liver disease;\n* Person with alcohol misuse, defined by a weekly consumption of more than 10 standard units;\n* Person with a morphotype that does not allow an MRI examination to be performed;\n* Woman of childbearing age who does not have an effective means of contraception;\n* Contraindication to performing an MRI examination.\n* Person referred to in Articles L. 1121-5, L. 1121-7 and L1121-8 of the French Public Health Code.",{"count":467,"type":19},21,[291],"The main hypothesis of the HEPACORT study is that upon diagnosis of endogenous Cushing's syndrome, significant liver fibrosis may be present, particularly in the most severe forms of Cushing's syndrome.\n\nthe HEPACORT study is the first exploratory study to assess the severity of liver fibrosis in patients with Cushing's syndrome or suspected of presenting by Magnetic Resonance Elastography (MRE).",[26,471],"Metabolic Syndrome","2023-10-24",{"date":474,"type":36},"2023-10-25",{"date":472,"type":36},{"date":477,"type":19},"2026-08-31",{"name":479,"class":97},"Central Hospital, Nancy, France",{"id":481,"slug":482,"hasResults":11,"nctId":483,"briefTitle":484,"officialTitle":485,"acronym":4,"eligibilityCriteria":486,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":487,"targetDuration":4,"studyType":81,"phases":4,"briefSummary":488,"conditions":489,"keywords":500,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":504,"lastUpdatePostDateStruct":505,"startDateStruct":507,"completionDateStruct":509,"leadSponsor":511,"locationsCount":44},"100519938","surgical-treatment-of-adrenal-diseases--laparoscopic-vs-robotic-assisted-adrenalectomy-100519938","NCT06050057","Surgical Treatment of Adrenal Diseases- Laparoscopic vs. Robotic-assisted Adrenalectomy","Possibilities of Surgical Treatment of Adrenal Diseases: Comparison of Laparoscopic and Robotic-assisted Adrenalectomy-a Prospective Study","Inclusion Criteria:\n\n* Indicated adrenalectomy based on endocrinological and imaging examination.\n* Written consent to participate in the study.\n\nExclusion Criteria:\n\n* Simultaneous bilateral adrenalectomy.\n* Adrenal expansion \\> 12 cm.\n* Suspected malignant adrenal tumor with infiltrative growth or tumor venous thrombus according to imaging examination.",{"count":321,"type":19},"The goal of this multicenter, observational, analytic, randomized clinical trial is to analyze the laparoscopic and robot-assisted method in the surgical treatment of patients with adrenal diseases. The main question it aims to answer are:\n\n1. to find the superiority of one the the surgical method mentioned above\n2. to compare the quality of life in patients with adrenal mass before surgery and after laparoscopic or robotic-assisted adrenalectomy.",[490,491,492,493,494,495,496,87,26,497,85,498,499],"Adrenal Tumor","Adrenal Disease","Adrenal Mass","Adrenalectomy; Status","Adrenal Hyperplasia","Adrenal Gland Metastasis","Adrenal Cortex Diseases","Conn Adenoma","Adrenocortical Adenoma","Adrenocortical Tumor",[490,87,497,26,501,502,503],"Adrenalectomy","Laparoscopic surgery","da Vinci surgical system","2023-09-17",{"date":506,"type":36},"2023-09-22",{"date":508,"type":36},"2023-09-03",{"date":510,"type":19},"2026-06-30",{"name":512,"class":97},"University Hospital Olomouc"]